Home/Filings/4/0001116502-09-000436
4//SEC Filing

Hamill John P 4

Accession 0001116502-09-000436

CIK 0001089542other

Filed

Mar 23, 8:00 PM ET

Accepted

Mar 24, 5:00 PM ET

Size

14.4 KB

Accession

0001116502-09-000436

Insider Transaction Report

Form 4
Period: 2009-03-20
Hamill John P
EVP and CFO
Transactions
  • Disposition to Issuer

    OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001

    2009-03-203,5710 total
    Exercise: $13.86COMMON STOCK, PAR VALUE $.001 (3,571 underlying)
  • Disposition from Tender

    Common Stock, Par value $.001

    2009-03-20$5.00/sh45,396$226,9800 total
  • Disposition to Issuer

    OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001

    2009-03-204,5330 total
    Exercise: $26.91COMMON STOCK, PAR VALUE $.001 (4,533 underlying)
  • Disposition to Issuer

    OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001

    2009-03-204,8410 total
    Exercise: $29.47COMMON STOCK, PAR VALUE $.001 (4,841 underlying)
  • Disposition to Issuer

    OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001

    2009-03-208950 total
    Exercise: $40.39COMMON STOCK, PAR VALUE $.001 (895 underlying)
Footnotes (2)
  • [F1]Of such amount, 16,214 shares automatically vested and were paid for in connection with the change in control which occurred upon the acceptance of shares pursuant to the tender offer (the "Offer") which was launched in connection with the Agreement and Plan of Merger dated February 3, 2009 by and among JLL PharmaNet Holdings, LLC ("Parent"), PDGI Acquisition Corp. ("Purchaser") and PharmaNet ("PharmaNet"). Mr. Hamill has not immediately received the funds associated with this vesting pursuant to Internal Revenue Code 409A. On March 20, 2009, all shares which were tendered by the filing person in connection with the Offer, were accepted by the Purchaser. Any shares which were not tendered by the filing person will be cashed out at the closing of the Merger.
  • [F2]Such options were canceled in connection with the Merger in exchange for the right to receive the difference between the merger consideration of $5.00 per share and the options exercise price.

Issuer

PharmaNet Development Group Inc

CIK 0001089542

Entity typeother

Related Parties

1
  • filerCIK 0001349581

Filing Metadata

Form type
4
Filed
Mar 23, 8:00 PM ET
Accepted
Mar 24, 5:00 PM ET
Size
14.4 KB